Tags

Type your tag names separated by a space and hit enter

Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Infect Control Hosp Epidemiol. 2007 Jun; 28(6):695-701.IC

Abstract

OBJECTIVE

To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF).

METHODS

Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP.

SETTING

University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center.

PARTICIPANTS

Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure.

CONCLUSION

Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Luque A
Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. amneris_luque@urmc.rochester.edu
Hulse S
No affiliation info available
Wang D
No affiliation info available
Shahzad U
No affiliation info available
Tanzman E
No affiliation info available
Antenozzi S
No affiliation info available
Smith B
No affiliation info available

MeSH

AdenineAdultAnti-HIV AgentsChemopreventionDrug CombinationsFemaleHIV InfectionsHumansLamivudineLogistic ModelsMaleMiddle AgedNew YorkOccupational ExposureOccupational Health ServicesOrganophosphonatesPatient CompliancePublic Health AdministrationRetrospective StudiesRisk FactorsSex FactorsStudent Health ServicesTenofovirUniversitiesZidovudine

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

17520543

Citation

Luque, A, et al. "Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus." Infection Control and Hospital Epidemiology, vol. 28, no. 6, 2007, pp. 695-701.
Luque A, Hulse S, Wang D, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701.
Luque, A., Hulse, S., Wang, D., Shahzad, U., Tanzman, E., Antenozzi, S., & Smith, B. (2007). Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infection Control and Hospital Epidemiology, 28(6), 695-701.
Luque A, et al. Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701. PubMed PMID: 17520543.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. AU - Luque,A, AU - Hulse,S, AU - Wang,D, AU - Shahzad,U, AU - Tanzman,E, AU - Antenozzi,S, AU - Smith,B, Y1 - 2007/05/08/ PY - 2006/07/25/received PY - 2006/10/27/accepted PY - 2007/5/24/pubmed PY - 2008/2/7/medline PY - 2007/5/24/entrez SP - 695 EP - 701 JF - Infection control and hospital epidemiology JO - Infect Control Hosp Epidemiol VL - 28 IS - 6 N2 - OBJECTIVE: To assess adverse events associated with antiretroviral regimens for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP), with a particular focus on the treatment combination of zidovudine, lamivudine, and tenofovir (ZDV-3TC-TDF). METHODS: Retrospective chart review for individuals who received HIV PEP for occupational and nonoccupational exposure, and multivariate analyses to identify risk factors for noncompletion of PEP and adverse events associated with PEP. SETTING: University of Rochester Health Service Occupational Health Program and University of Rochester AIDS Center. PARTICIPANTS: Healthcare workers who received HIV PEP for occupational exposure from January 1, 1999, to December 31, 2004, and individuals who received HIV PEP for nonoccupational exposure from January 1, 2002, to December 31, 2004.Results. We found increased rates of nausea among subjects who received treatment with ZDV-3TC-TDF and subjects who received treatment with zidovudine, lamivudine, and indinavir (ZDV-3TC-IDV). Analyses showed that female sex was a risk factor for nausea. Compared with subjects who received treatment with ZDV-3TC-TDF, subjects who received treatment with ZDV-3TC-IDV were less likely to not complete the HIV PEP for occupational exposure. CONCLUSION: Preventive treatment of adverse events may be necessary to ensure completion of HIV PEP. SN - 0899-823X UR - https://www.unboundmedicine.com/medline/citation/17520543/Assessment_of_adverse_events_associated_with_antiretroviral_regimens_for_postexposure_prophylaxis_for_occupational_and_nonoccupational_exposures_to_prevent_transmission_of_human_immunodeficiency_virus_ L2 - https://www.cambridge.org/core/product/identifier/ICHE2006244/type/journal_article DB - PRIME DP - Unbound Medicine ER -